Logo of commbiolLink to Publisher's site
PMC full text:
Published online 2021 Jun 10. doi: 10.1038/s42003-021-02251-6
Copyright/LicenseRequest permission to reuse

Fig. 7

An external file that holds a picture, illustration, etc. Object name is 42003_2021_2251_Fig7_HTML.jpg
Superior protection and survival provided by LV-β2m-OVA therapeutic immunization.

C57BL/6 mice (n = 6 for Ad5-CMV-OVA, LV-β2m-OVA, and PBS, n = 5 for Ad5-CMV-GFP and LV-β2m-GFP) were challenged subcutaneously with 3 × 106 E.G7 tumor cell line and were immunized with 5 × 107 TU of LV-β2m-OVA or 1 × 107 IGU Ad5-CMV-OVA at day 8 post engraftment when tumor volume averaged ~250 mm3. a The tumor volume for individual mouse overtime for the indicated immunization. b The tumor volume at 9 dpi (or 17 days post engraftment). c Percentages of antigen-specific T cells within the CD3+ CD8+ T subset in the blood at 9 dpi. For (b) and (c), black lines represent mean, dots represent biological replicates. d The percentage of survival at the indicated time points is shown.

Images in this article

  • Fig. 1
  • Fig. 2
  • Fig. 3
  • Fig. 4
  • Fig. 5
  • Fig. 6
  • Fig. 7

Click on the image to see a larger version.

-